Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Iza-bren · 4 trials · 3 indications
Phase 2
Phase 3
Assessed using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per blinded independent central review (BICR)
Assessed using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by blinded independent central review (BICR)
| Arm | Type | Description |
|---|---|---|
| Arm A | EXPERIMENTAL | - |
| Arm B | ACTIVE_COMPARATOR | - |
| Arm C | ACTIVE_COMPARATOR | - |
| Arm D | EXPERIMENTAL | - |
| Arm E | ACTIVE_COMPARATOR | - |
| Arm A1 | EXPERIMENTAL | - |
| Arm A2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Iza-bren | DRUG | Specified dose on specified days |
| Osimertinib | DRUG | Specified dose on days |
| Pemetrexed | DRUG | Specified dose on specified days |
| Carboplatin | DRUG | Specified dose on specified days |
| Cisplatin | DRUG | Specified dose on specified days |
| Gemcitabine | DRUG | Specified dose on specified days |
| Nab-paclitaxel | DRUG | Specified dose on specified days |
| Paclitaxel | DRUG | Specified dose on specified days |
| Capecitabine | DRUG | Specified dose on specified days |
Inclusion Criteria: * Participants must have histologically or cytologically confirmed non-squamous NSCLC, newly diagnosed locally advanced (Stage IIIB/IIIC), metastatic (Stage IVA/IVB), or recurrent disease not amenable to curative surgery or definitive radiotherapy and requiring systemic treatmen...
Top 20 of 83 competitors
Iza-bren, also known as Izalontamab Brengitecan and BMS-986507, is an investigational small molecule being developed by Bristol-Myers Squibb for oncology indications. It is currently in Phase 2 clinical trials for urothelial cancer, breast neoplasms, and non-small cell lung cancer.
Iza-bren is being studied for the treatment of urothelial cancer, breast neoplasms, and non-small cell lung cancer. In clinical trials, it is being evaluated as a monotherapy and in combination with other agents for these advanced or metastatic cancers.
Iza-bren is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting multiple clinical trials to evaluate the drug's safety and efficacy in various oncology indications.
Iza-bren is currently in Phase 2 clinical development. It is being studied in active trials for urothelial cancer, breast neoplasms, and non-small cell lung cancer. The drug is investigational and has not been approved by regulatory authorities.
Iza-bren is being evaluated in several recruiting trials, including NCT06926868 for triple-negative breast cancer, NCT07100080 for EGFR-mutated non-small cell lung cancer, and NCT07106762 for metastatic urothelial cancer. These trials are actively enrolling participants.
Yes, Iza-bren is the same as Izalontamab Brengitecan, which is also known by the code BMS-986507. These names refer to the same investigational drug being developed by Bristol-Myers Squibb for oncology indications.